Current vascular pharmacology · 2026
Antithrombotic Therapy in Patients with Chronic Coronary Disease on Anticoagulation: Evidence from Contemporary Trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reddy Sukhila, Kattamuri Lakshmi, Asif Muhammad, Mukherjee Debabrata
Аннотация
INTRODUCTION: Chronic coronary disease (CCD) commonly coexists with long-term oral anticoagulation (OAC), particularly for atrial fibrillation (AF). Combination antiplatelet therapy increases bleeding, whereas ischemic protection with OAC alone remains a concern. We critically appraised contemporary evidence and guidelines to define optimal long-term maintenance therapy.
METHODS: We synthesized WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, AFIRE, OAC-ALONE, PRAEDO-AF, EPIC-CAD, AQUATIC, and meta-analyses. Because foundational trials included recent ACS/PCI populations, evidence was analyzed as early/recent ACS or PCI (≤1 year) and late/stable CAD (>1 year post-PCI or non-revascularized CCD). Designs, populations, ischemic, bleeding, and mortality outcomes were systematically compared within the 2023 ACC/AHA CCD and AF guidelines.
RESULTS AND DISCUSSION: Early trials supported aspirin withdrawal and DOAC plus single P2Y12 inhibition after PCI. Later trials showed full-dose OAC monotherapy was noninferior to OAC plus single antiplatelet therapy beyond 6-12 months or in stable non-revascularized CCD for preventing myocardial infarction, stroke, and systemic embolism, while reducing major and clinically relevant nonmajor bleeding and, sometimes, mortality. Meta-analysis showed fewer cardiovascular death, myocardial infarction, stroke, and major bleeding events without excess ischemia.
CONCLUSION: OAC monotherapy should be the default for most patients, reserving antiplatelets for individualized high-ischemic/low-bleeding-risk scenarios, while recognizing predominantly East Asian and limited European evidence.
METHODS: We synthesized WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, AFIRE, OAC-ALONE, PRAEDO-AF, EPIC-CAD, AQUATIC, and meta-analyses. Because foundational trials included recent ACS/PCI populations, evidence was analyzed as early/recent ACS or PCI (≤1 year) and late/stable CAD (>1 year post-PCI or non-revascularized CCD). Designs, populations, ischemic, bleeding, and mortality outcomes were systematically compared within the 2023 ACC/AHA CCD and AF guidelines.
RESULTS AND DISCUSSION: Early trials supported aspirin withdrawal and DOAC plus single P2Y12 inhibition after PCI. Later trials showed full-dose OAC monotherapy was noninferior to OAC plus single antiplatelet therapy beyond 6-12 months or in stable non-revascularized CCD for preventing myocardial infarction, stroke, and systemic embolism, while reducing major and clinically relevant nonmajor bleeding and, sometimes, mortality. Meta-analysis showed fewer cardiovascular death, myocardial infarction, stroke, and major bleeding events without excess ischemia.
CONCLUSION: OAC monotherapy should be the default for most patients, reserving antiplatelets for individualized high-ischemic/low-bleeding-risk scenarios, while recognizing predominantly East Asian and limited European evidence.